-
1
-
-
33747830764
-
Hepatocellular carcinoma pathogenesis: from genes to environment
-
Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 674-687
-
-
Farazi, P.A.1
DePinho, R.A.2
-
3
-
-
20444445580
-
P53 mutations in hepatocellular carcinoma patients in Egypt
-
El-Kafrawy S.A., Abdel-Hamid M., El-Daly M., Nada O., Ismail A., Ezzat S., et al. P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health 208 (2005) 263-270
-
(2005)
Int J Hyg Environ Health
, vol.208
, pp. 263-270
-
-
El-Kafrawy, S.A.1
Abdel-Hamid, M.2
El-Daly, M.3
Nada, O.4
Ismail, A.5
Ezzat, S.6
-
4
-
-
0034162524
-
p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride
-
Weihrauch M., Lehnert G., Kockerling F., Wittekind C., and Tannapfel A. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 88 (2000) 1030-1036
-
(2000)
Cancer
, vol.88
, pp. 1030-1036
-
-
Weihrauch, M.1
Lehnert, G.2
Kockerling, F.3
Wittekind, C.4
Tannapfel, A.5
-
5
-
-
0034818446
-
Post-translational modifications and activation of p53 by genotoxic stresses
-
Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268 (2001) 2764-2772
-
(2001)
Eur J Biochem
, vol.268
, pp. 2764-2772
-
-
Appella, E.1
Anderson, C.W.2
-
6
-
-
0037329056
-
The p53-MDM2 module and the ubiquitin system
-
Michael D., and Oren M. The p53-MDM2 module and the ubiquitin system. Semin Cancer Biol 13 (2003) 49-58
-
(2003)
Semin Cancer Biol
, vol.13
, pp. 49-58
-
-
Michael, D.1
Oren, M.2
-
7
-
-
14644437751
-
MDM2 is a central node in the p53 pathway: 12 years and counting
-
Bond G.L., Hu W., and Levine A.J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5 (2005) 3-8
-
(2005)
Curr Cancer Drug Targets
, vol.5
, pp. 3-8
-
-
Bond, G.L.1
Hu, W.2
Levine, A.J.3
-
8
-
-
0037220737
-
mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation
-
Mendrysa S.M., McElwee M.K., Michalowski J., O'Leary K.A., Young K.M., and Perry M.E. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23 (2003) 462-472
-
(2003)
Mol Cell Biol
, vol.23
, pp. 462-472
-
-
Mendrysa, S.M.1
McElwee, M.K.2
Michalowski, J.3
O'Leary, K.A.4
Young, K.M.5
Perry, M.E.6
-
9
-
-
0032417695
-
Overexpression of MDM2 in mice reveals a p53-independent role for MDM2 in tumorigenesis
-
Jones S.N., Hancock A.R., Vogel H., Donehower L.A., and Bradley A. Overexpression of MDM2 in mice reveals a p53-independent role for MDM2 in tumorigenesis. Proc Natl Acad Sci USA 95 (1998) 15608-15612
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 15608-15612
-
-
Jones, S.N.1
Hancock, A.R.2
Vogel, H.3
Donehower, L.A.4
Bradley, A.5
-
10
-
-
8844278362
-
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
-
Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
-
(2004)
Cell
, vol.119
, pp. 591-602
-
-
Bond, G.L.1
Hu, W.2
Bond, E.E.3
Robins, H.4
Lutzker, S.G.5
Arva, N.C.6
-
11
-
-
33748344945
-
MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C
-
Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12 (2006) 4867-4871
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4867-4871
-
-
Dharel, N.1
Kato, N.2
Muroyama, R.3
Moriyama, M.4
Shao, R.X.5
Kawabe, T.6
-
12
-
-
0029028354
-
Interaction between the retinoblastoma protein and the oncoprotein MDM2
-
Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375 (1995) 694-698
-
(1995)
Nature
, vol.375
, pp. 694-698
-
-
Xiao, Z.X.1
Chen, J.2
Levine, A.J.3
Modjtahedi, N.4
Xing, J.5
Sellers, W.R.6
-
13
-
-
0033082231
-
RB regulates the stability and the apoptotic function of p53 via MDM2
-
Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., and Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3 (1999) 181-193
-
(1999)
Mol Cell
, vol.3
, pp. 181-193
-
-
Hsieh, J.K.1
Chan, F.S.2
O'Connor, D.J.3
Mittnacht, S.4
Zhong, S.5
Lu, X.6
-
15
-
-
33749040649
-
MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis
-
Ohmiya N., Taguchi A., Mabuchi N., Itoh A., Hirooka Y., Niwa Y., et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24 (2006) 4434-4440
-
(2006)
J Clin Oncol
, vol.24
, pp. 4434-4440
-
-
Ohmiya, N.1
Taguchi, A.2
Mabuchi, N.3
Itoh, A.4
Hirooka, Y.5
Niwa, Y.6
-
16
-
-
33750297735
-
MDM2 309T>G polymorphism and risk of lung cancer in a Korean population
-
Park S.H., Choi J.E., Kim E.J., Jang J.S., Han H.S., Lee W.K., et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 54 (2006) 19-24
-
(2006)
Lung Cancer
, vol.54
, pp. 19-24
-
-
Park, S.H.1
Choi, J.E.2
Kim, E.J.3
Jang, J.S.4
Han, H.S.5
Lee, W.K.6
-
17
-
-
33749546905
-
MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis
-
Li G., Zhai X., Zhang Z., Chamberlain R.M., Spitz M.R., and Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27 (2006) 2028-2033
-
(2006)
Carcinogenesis
, vol.27
, pp. 2028-2033
-
-
Li, G.1
Zhai, X.2
Zhang, Z.3
Chamberlain, R.M.4
Spitz, M.R.5
Wei, Q.6
-
18
-
-
33746239400
-
Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population
-
Ma H., Hu Z., Zhai X., Wang S., Wang X., Qin J., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240 (2006) 261-267
-
(2006)
Cancer Lett
, vol.240
, pp. 261-267
-
-
Ma, H.1
Hu, Z.2
Zhai, X.3
Wang, S.4
Wang, X.5
Qin, J.6
-
19
-
-
33744918197
-
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
-
Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., and Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119 (2006) 718-721
-
(2006)
Int J Cancer
, vol.119
, pp. 718-721
-
-
Lind, H.1
Zienolddiny, S.2
Ekstrom, P.O.3
Skaug, V.4
Haugen, A.5
-
20
-
-
33750690647
-
MDM2 T309G polymorphism is associated with bladder cancer
-
Onat O.E., Tez M., Ozcelik T., and Toruner G.A. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 26 (2006) 3473-3475
-
(2006)
Anticancer Res
, vol.26
, pp. 3473-3475
-
-
Onat, O.E.1
Tez, M.2
Ozcelik, T.3
Toruner, G.A.4
-
21
-
-
33845944092
-
Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk
-
Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya H.S., Gur-Dedeoglu B., and Yulug I.G. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26 (2006) 4975-4977
-
(2006)
Anticancer Res
, vol.26
, pp. 4975-4977
-
-
Petenkaya, A.1
Bozkurt, B.2
Akilli-Ozturk, O.3
Kaya, H.S.4
Gur-Dedeoglu, B.5
Yulug, I.G.6
-
22
-
-
33645459643
-
No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites
-
Millikan R.C., Heard K., Winkel S., Hill E.J., Heard K., Massa B., et al. No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15 (2006) 175-177
-
(2006)
Cancer Epidemiol Biomarkers Prev
, vol.15
, pp. 175-177
-
-
Millikan, R.C.1
Heard, K.2
Winkel, S.3
Hill, E.J.4
Heard, K.5
Massa, B.6
-
23
-
-
33746218700
-
No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
-
Campbell I.G., Eccles D.M., and Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240 (2006) 195-197
-
(2006)
Cancer Lett
, vol.240
, pp. 195-197
-
-
Campbell, I.G.1
Eccles, D.M.2
Choong, D.Y.3
-
24
-
-
24944454674
-
The MDM2 promoter polymorphism SNP309T → G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck
-
Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., Bono P., Arola J., Jarvinen H.J., et al. The MDM2 promoter polymorphism SNP309T → G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42 (2005) 694-698
-
(2005)
J Med Genet
, vol.42
, pp. 694-698
-
-
Alhopuro, P.1
Ylisaukko-Oja, S.K.2
Koskinen, W.J.3
Bono, P.4
Arola, J.5
Jarvinen, H.J.6
-
25
-
-
33744899069
-
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
-
Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66 (2006) 5104-5110
-
(2006)
Cancer Res
, vol.66
, pp. 5104-5110
-
-
Bond, G.L.1
Hirshfield, K.M.2
Kirchhoff, T.3
Alexe, G.4
Bond, E.E.5
Robins, H.6
-
26
-
-
3242675012
-
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
-
Bianco R., Caputo R., Caputo R., Damiano V., De Placido S., Ficorella C., et al. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res 10 (2004) 4858-4864
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4858-4864
-
-
Bianco, R.1
Caputo, R.2
Caputo, R.3
Damiano, V.4
De Placido, S.5
Ficorella, C.6
-
27
-
-
14644439903
-
Chemosensitization by antisense oligonucleotides targeting MDM2
-
Bianco R., Ciardiello F., and Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets 5 (2005) 51-56
-
(2005)
Curr Cancer Drug Targets
, vol.5
, pp. 51-56
-
-
Bianco, R.1
Ciardiello, F.2
Tortora, G.3
-
28
-
-
33745527481
-
Viral hepatitis and liver cancer: the case of hepatitis C
-
Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25 (2006) 3834-3847
-
(2006)
Oncogene
, vol.25
, pp. 3834-3847
-
-
Levrero, M.1
-
29
-
-
27644571181
-
MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia
-
Swinney R.M., Hsu S.C., Hirschman B.A., Chen T.T., and Tomlinson G.E. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia 19 (2005) 1996-1998
-
(2005)
Leukemia
, vol.19
, pp. 1996-1998
-
-
Swinney, R.M.1
Hsu, S.C.2
Hirschman, B.A.3
Chen, T.T.4
Tomlinson, G.E.5
|